```html

Zollinger‑Ellison Gastrinoma: A Patient‑Centred Medical Guide

Overview

Zollinger‑Ellison syndrome (ZES) is a rare condition caused by a gastrin‑producing tumor called a gastrinoma. Gastrinomas are neuroendocrine tumors (NETs) that secrete excessive amounts of gastrin, a hormone that stimulates the stomach lining to produce large volumes of acid. The resulting hyperacidity leads to severe peptic ulcers, diarrhea, and other gastrointestinal problems.

Who it affects

• Adults between 30–60 years are most commonly diagnosed, but cases occur in children and adolescents.
• Both sexes are affected; a slight male predominance (≈55 % male) has been reported.
• Approximately 20‑30 % of cases occur as part of the inherited syndrome multiple endocrine neoplasia type 1 (MEN‑1).

Prevalence

• Overall incidence of gastrinomas is ~1–3 per million people per year.
• Zollinger‑Ellison syndrome accounts for roughly 0.1 % of all peptic ulcer disease cases.
• In the United States, an estimated 500–800 new cases are diagnosed annually.

Because the disease is rare, many patients experience delayed diagnosis, often several years after symptom onset.

Symptoms

Symptoms stem from two major mechanisms: (1) excess gastric acid and (2) hormone‑producing effects of the tumor itself.

Gastric‑acid related symptoms

• Refractory peptic ulcers – ulcer pain that does not improve with standard proton‑pump inhibitor (PPI) therapy; ulcers may be multiple and located beyond the duodenum (e.g., jejunum).
• Abdominal pain – burning or gnawing pain, often worse after meals.
• Heartburn / gastro‑esophageal reflux disease (GERD) – due to high acid load.
• Upper gastrointestinal (GI) bleeding – manifested as melena or hematemesis.

Gastro‑intestinal motility and secretory symptoms

• Chronic watery diarrhea – occurs in up to 50 % of patients; can lead to dehydration and electrolyte disturbances.
• Steatorrhea (fatty stools) – malabsorption caused by acid‑induced inactivation of pancreatic enzymes.
• Nausea & vomiting – especially after large meals.

Systemic / tumor‑related symptoms

• Weight loss – from malabsorption and decreased appetite.
• Fatigue – secondary to anemia from chronic GI bleeding.
• Flushing, itching, or wheezing – rare, but may indicate hormone‑producing metastases.

Causes and Risk Factors

Primary causes

• Spontaneous (sporadic) gastrinoma – ~70 % arise without an identifiable genetic syndrome.
• MEN‑1 syndrome – an autosomal‑dominant disorder caused by mutations in the MEN1 gene; patients develop multiple endocrine tumors (parathyroid, pituitary, pancreatic). Gastrinomas in MEN‑1 are often multiple and located in the duodenum.

Risk factors

• Family history of MEN‑1 or other endocrine neoplasias.
• Known genetic mutations in MEN1 or CDKN1B (rare).
• Chronic gastritis or H. pylori infection does not increase gastrinoma risk, but may mask or complicate diagnosis.

Diagnosis

Diagnosis requires a combination of clinical suspicion, biochemical testing, and imaging.

Biochemical tests

• Fasting serum gastrin level – a level > 1000 pg/mL (normal < 100 pg/mL) strongly suggests ZES, especially when paired with gastric pH < 2.
• Secretin stimulation test – after intravenous secretin, gastrin rises > 120 pg/mL in ZES; this test improves specificity when basal gastrin is modestly elevated.
• Gastric pH measurement – an acidic pH (< 2) despite high gastrin confirms hyperacidic state.

Imaging studies

• Contrast‑enhanced CT or MRI – first‑line to locate primary tumor and assess for metastasis, especially hepatic lesions.
• Somatostatin receptor scintigraphy (Octreoscan) or 68Ga‑DOTATATE PET/CT – highly sensitive for neuroendocrine tumors, detecting lesions < 5 mm.
• EUS (Endoscopic Ultrasound) – excellent for small duodenal gastrinomas and for fine‑needle aspiration (FNA) biopsy.
• Selective arterial secretin stimulation test (SASS) – used when non‑invasive imaging is inconclusive; measures gastrin from specific arterial territories.

Pathology

If tissue is obtained, histology shows uniform neuroendocrine cells positive for chromogranin A, synaptophysin, and gastrin immunostaining. Ki‑67 proliferative index helps grade the tumor (G1‑G3).

Treatment Options

Management is twofold: control acid hypersecretion and eradicate or control the tumor.

Acid‑suppression therapy (essential for all patients)

• Proton Pump Inhibitors (PPIs) – high‑dose regimens (e.g., omeprazole 60–120 mg/day or equivalent) are first‑line; they heal ulcers and control diarrhea.
• H2‑receptor antagonists – useful adjuncts or alternatives if PPIs are not tolerated, though less effective for severe hyperacidity.

Surgical approaches

• Curative resection – preferred for solitary, non‑metastatic tumors; pancreaticoduodenectomy (Whipple) or local excision for duodenal lesions.
• Debulking surgery – reduces tumor burden when complete resection is impossible; improves symptom control.
• Enucleation – for small (< 2 cm) pancreatic gastrinomas without involvement of major ducts.

Medical therapies for unresectable or metastatic disease

• Somatostatin analogues (e.g., octreotide, lanreotide) – inhibit gastrin release and may stabilize tumor growth.
• Targeted therapy – everolimus (mTOR inhibitor) and sunitinib (tyrosine‑kinase inhibitor) have shown benefit in advanced pancreatic NETs.
• Peptide receptor radionuclide therapy (PRRT) – 177Lu‑DOTATATE delivers radiation directly to somatostatin‑receptor‑positive tumors; FDA‑approved for metastatic NETs.
• Chemotherapy – generally reserved for high‑grade (G3) neuroendocrine carcinomas; regimens include streptozocin‑based combos.

Liver-directed therapies (for hepatic metastases)

• Radiofrequency ablation, trans‑arterial chemoembolization (TACE), or Y‑90 radioembolization.

Lifestyle and supportive care

• Eat small, frequent meals; avoid foods that trigger reflux (caffeine, alcohol, spicy foods).
• Maintain adequate hydration; replace electrolytes if diarrhea is severe.
• Screen for and treat osteoporosis (chronic PPI use can affect bone density).
• Regular surveillance endoscopy every 1–2 years to monitor ulcer healing.

Living with Zollinger’s Gastrinoma

Daily management tips

• Medication adherence – take PPIs exactly as prescribed; timing (30 min before a meal) maximizes effect.
• Monitor symptoms – keep a diary of pain, stool frequency, and any bleeding; share trends with your gastroenterologist.
• Nutrition – a dietitian can design a low‑fat, low‑simple‑sugar plan to minimize steatorrhea.
• Vaccinations – patients on long‑term PPIs or immunosuppressive therapy (e.g., everolimus) should receive pneumococcal, influenza, and COVID‑19 vaccines.
• Exercise – moderate activity (e.g., walking, swimming) improves gut motility and overall well‑being.
• Psychosocial support – joining a NET support group can reduce anxiety and provide practical coping strategies.

Follow‑up schedule

• Every 3–6 months: serum gastrin, liver function tests, and imaging (CT/MRI) if metastatic.
• Annually: octreotide scan or 68Ga‑DOTATATE PET/CT to evaluate for new lesions.
• Endoscopy: every 1–2 years or sooner if ulcer symptoms recur.

Prevention

Because most gastrinomas are sporadic, primary prevention is limited. However, certain steps can reduce risk or aid early detection:

• Genetic counseling for families with MEN‑1; early screening with fasting gastrin and imaging can identify tumors before complications.
• Avoid chronic use of non‑steroidal anti‑inflammatory drugs (NSAIDs) – they aggravate ulcer formation and may mask early symptoms.
• Prompt evaluation of refractory ulcer disease – seeking care after 8–12 weeks of persistent ulcer pain despite PPI therapy improves early diagnosis.

Complications

If left untreated or inadequately controlled, Zollinger‑Ellison syndrome can lead to serious health problems:

• Bleeding ulcers – may cause anemia, hemodynamic instability, or require endoscopic/surgical intervention.
• Perforation of the GI tract – a surgical emergency with risk of peritonitis.
• Severe malabsorption – chronic diarrhea and steatorrhea can cause weight loss, vitamin A/D/K deficiencies, and osteopenia.
• Metastatic disease – liver is the most common site; metastases reduce survival (5‑year survival ≈ 60 % for localized disease vs. 30 % for metastatic).
• Electrolyte disturbances – low potassium, magnesium, and bicarbonate from chronic diarrhea.
• Secondary infections – high-dose PPIs increase risk of Clostridioides difficile infection.

When to Seek Emergency Care

References

1. Mayo Clinic. Zollinger‑Ellison syndrome. Updated 2023. https://www.mayoclinic.org.
2. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Neuroendocrine Tumors (NETs). 2022. https://www.niddk.nih.gov.
3. Cleveland Clinic. Zollinger‑Ellison syndrome: Diagnosis and treatment. 2023. https://my.clevelandclinic.org.
4. WHO Classification of Tumours of the Digestive System, 5th Ed., 2020.
5. Smith, J. et al. “Outcomes of surgery for sporadic gastrinomas.” Ann Surg Oncol. 2021;28(5):2871‑2879.
6. European Neuroendocrine Tumor Society (ENETS) Guidelines for Neuroendocrine Tumors, 2022.

```